Tags

Type your tag names separated by a space and hit enter

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.
J Cachexia Sarcopenia Muscle. 2016 May; 7(2):126-35.JC

Abstract

BACKGROUND AND AIMS

Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients.

METHODS

We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body mass index-specific cutoffs.

RESULTS

Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%), alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353 had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.44-2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02-1.07, P = 0.04) were associated with mortality.

CONCLUSIONS

Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.

Authors+Show Affiliations

Division of Gastroenterology & Liver Unit University of Alberta Hospital Edmonton Alberta Canada.Division of Digestive Diseases & Nutrition University of Kentucky Medical Center Lexington KY USA.Department of Oncology Cross Cancer Institute Edmonton Alberta Canada.Department of Agricultural Food and Nutritional Sciences Edmonton Alberta Canada.Department of Oncology Cross Cancer Institute Edmonton Alberta Canada.Department of Oncology Cross Cancer Institute Edmonton Alberta Canada.Department of Oncology Cross Cancer Institute Edmonton Alberta Canada.Division of Gastroenterology & Liver Unit University of Alberta Hospital Edmonton Alberta Canada.Department of Oncology Cross Cancer Institute Edmonton Alberta Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27493866

Citation

Montano-Loza, Aldo J., et al. "Sarcopenic Obesity and Myosteatosis Are Associated With Higher Mortality in Patients With Cirrhosis." Journal of Cachexia, Sarcopenia and Muscle, vol. 7, no. 2, 2016, pp. 126-35.
Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7(2):126-35.
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016). Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 7(2), 126-35. https://doi.org/10.1002/jcsm.12039
Montano-Loza AJ, et al. Sarcopenic Obesity and Myosteatosis Are Associated With Higher Mortality in Patients With Cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7(2):126-35. PubMed PMID: 27493866.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. AU - Montano-Loza,Aldo J, AU - Angulo,Paul, AU - Meza-Junco,Judith, AU - Prado,Carla M M, AU - Sawyer,Michael B, AU - Beaumont,Crystal, AU - Esfandiari,Nina, AU - Ma,Mang, AU - Baracos,Vickie E, Y1 - 2015/06/09/ PY - 2014/12/12/received PY - 2015/03/16/revised PY - 2015/04/09/accepted PY - 2016/8/6/entrez PY - 2016/8/6/pubmed PY - 2016/8/6/medline KW - Cirrhosis KW - Lumbar skeletal muscle index KW - Muscle attenuation index KW - Muscle depletion KW - Myosteatosis KW - Overweight SP - 126 EP - 35 JF - Journal of cachexia, sarcopenia and muscle JO - J Cachexia Sarcopenia Muscle VL - 7 IS - 2 N2 - BACKGROUND AND AIMS: Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients. METHODS: We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body mass index-specific cutoffs. RESULTS: Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%), alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353 had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.44-2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02-1.07, P = 0.04) were associated with mortality. CONCLUSIONS: Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia and myosteatosis are independently associated with a higher long-term mortality in cirrhosis. SN - 2190-5991 UR - https://www.unboundmedicine.com/medline/citation/27493866/Sarcopenic_obesity_and_myosteatosis_are_associated_with_higher_mortality_in_patients_with_cirrhosis_ L2 - https://dx.doi.org/10.1002/jcsm.12039 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.